Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors.
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antineoplastic Agents, Immunological
/ administration & dosage
B7-H1 Antigen
/ biosynthesis
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Female
Humans
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Muscle, Skeletal
/ diagnostic imaging
Nivolumab
/ administration & dosage
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Progression-Free Survival
Retrospective Studies
Nivolumab
Non-small cell lung cancer
Pembrolizumab
Predictive factor
Prognostic factor
Sarcopenia
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
11
11
2019
accepted:
01
02
2020
pubmed:
7
2
2020
medline:
18
4
2020
entrez:
7
2
2020
Statut:
ppublish
Résumé
The aim of this study was to elucidate the clinical impact of skeletal muscle area (SMA) in patients with non-small cell lung cancer (NSCLC) treated with anti-programmed cell death-1 (PD-1) inhibitors. Univariate and multivariate analyses were performed on data of 103 patients with advanced or recurrent NSCLC treated with anti-PD-1 inhibitors. The SMA was measured at the level of the third lumbar vertebral (L3) on computed tomography images using OsiriX software (32-bit, version 5.8; OsiriX, Geneva, Switzerland). The L3 muscle index (cm L3 muscle index L3 muscle index
Identifiants
pubmed: 32025867
doi: 10.1007/s00432-020-03146-5
pii: 10.1007/s00432-020-03146-5
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
B7-H1 Antigen
0
CD274 protein, human
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Nivolumab
31YO63LBSN
pembrolizumab
DPT0O3T46P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1217-1225Références
Eur J Appl Physiol. 2010 Sep;110(1):57-65
pubmed: 20390291
Ann Oncol. 2016 Jul;27(7):1354-6
pubmed: 27037297
Am J Clin Nutr. 1989 Nov;50(5 Suppl):1121-235
pubmed: 2816807
Invest New Drugs. 2017 Aug;35(4):436-441
pubmed: 28396974
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Ann Oncol. 2017 Aug 1;28(8):1949-1956
pubmed: 28472437
Curr Opin Support Palliat Care. 2009 Dec;3(4):269-75
pubmed: 19667996
J Cancer Surviv. 2012 Dec;6(4):398-406
pubmed: 23054848
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
J Thorac Oncol. 2016 Apr;11(4):487-95
pubmed: 26916631
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
J Cachexia Sarcopenia Muscle. 2016 Sep;7(4):458-66
pubmed: 27030813
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
Lung Cancer. 2016 Nov;101:92-97
pubmed: 27794415
Ann Surg Oncol. 2018 May;25(5):1229-1236
pubmed: 29327178
Br J Cancer. 2017 Jan;116(3):310-317
pubmed: 28072766
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
J Thorac Oncol. 2017 Dec;12(12):1798-1805
pubmed: 28939128
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006
pubmed: 18923576
Nutrition. 2001 May;17(5):438-42
pubmed: 11377146
J Immunother Cancer. 2019 Feb 27;7(1):57
pubmed: 30813970
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Lung Cancer. 2017 Oct;112:25-34
pubmed: 29191597
Cancer Res. 2005 Aug 15;65(16):7276-82
pubmed: 16105816
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Sci Rep. 2019 Feb 21;9(1):2447
pubmed: 30792455
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
J Thorac Oncol. 2015 Dec;10(12):1795-9
pubmed: 26484630
Age Ageing. 2010 Jul;39(4):412-23
pubmed: 20392703
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Lancet Oncol. 2013 Apr;14(4):335-45
pubmed: 23499390
Lancet Oncol. 2016 Apr;17(4):519-531
pubmed: 26906526
J Clin Med. 2019 Apr 03;8(4):
pubmed: 30987236
Clin Nutr. 2016 Dec;35(6):1557-1563
pubmed: 26922142
JAMA Oncol. 2020 Apr 1;6(4):512-518
pubmed: 31876896
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
Hepatol Res. 2016 Nov;46(12):1247-1255
pubmed: 26880049
J Cachexia Sarcopenia Muscle. 2017 Aug;8(4):598-606
pubmed: 28474432
J Am Med Dir Assoc. 2013 Mar;14(3):170-8
pubmed: 23276432
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
Lung Cancer. 2020 Jan;139:140-145
pubmed: 31786476
Eur J Cancer. 2016 Apr;57:58-67
pubmed: 26882087
Oncologist. 2016 Nov;21(11):1396-1409
pubmed: 27412391
J Nutr. 1997 May;127(5 Suppl):990S-991S
pubmed: 9164280